AKT1 E17K in colorectal carcinoma is associated with BRAF V600E but not MSI-H status: A clinicopathologic comparison to PIK3CA helical and kinase domain mutants

Molecular Cancer Research

Volumn 13, Issue 6, 2015, Pages 1003-1008

  Hechtman, Jaclyn F ^a   Sadowska, Justyna ^a   Huse, Jason T ^a   Borsu, Laetitia ^a   Yaeger, Rona ^a   Shia, Jinru ^a   Vakiani, Efsevia ^a   Ladanyi, Marc ^a   Arcila, Maria E ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AKT1 E17K PROTEIN; B RAF KINASE; CETUXIMAB; FLOXURIDINE; FLUOROURACIL; FOLINIC ACID; GENOMIC DNA; IRINOTECAN; K RAS PROTEIN; MISMATCH REPAIR PROTEIN; PHOSPHOINOSITIDE 3 KINASE CA PROTEIN; PHOSPHOTRANSFERASE; UNCLASSIFIED DRUG; YTTRIUM 90; AKT1 PROTEIN, HUMAN; ANTINEOPLASTIC AGENT; BRAF PROTEIN, HUMAN; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PIK3CA PROTEIN, HUMAN; PROTEIN KINASE B;

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER RESISTANCE; COLORECTAL CARCINOMA; DNA EXTRACTION; EXON; FEMALE; GENOTYPING TECHNIQUE; HISTOPATHOLOGY; HUMAN; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; MISSENSE MUTATION; MUTATION RATE; PRIORITY JOURNAL; ANTAGONISTS AND INHIBITORS; COHORT ANALYSIS; COLORECTAL NEOPLASMS; DRUG RESISTANCE; GENETICS; MICROSATELLITE INSTABILITY; MIDDLE AGED; MUTATION; PATHOPHYSIOLOGY; PROTEIN TERTIARY STRUCTURE; SIGNAL TRANSDUCTION;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CETUXIMAB; COHORT STUDIES; COLORECTAL NEOPLASMS; DRUG RESISTANCE, NEOPLASM; EXONS; FEMALE; HUMANS; MALE; MICROSATELLITE INSTABILITY; MIDDLE AGED; MUTATION; MUTATION RATE; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN STRUCTURE, TERTIARY; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 84942306431     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-15-0062-T     Document Type: Article

References (18)

1. Cully M, You H, Levine AJ, Mak TW. Beyond PTEN mutations: the PI3K pathway as an integrator ofmultiple inputs during tumorigenesis. Nat Rev Cancer 2006;6:184-92.
2. Samuels Y, Velculescu VE. Oncogenic mutations of PIK3CA in human cancers. Cell Cycle 2004;3:1221-4.
3. Rosty C, Young JP, Walsh MD, Clenndenning M, Sanderson K, Walters RJ, et al. PIK3CA activating mutation in colorectal carcinoma: associations with molecular features and survival. PLoS One 2013;8:e65479.
4. Day FL, Jorissen RN, Lipton L, Mouradov D, Sakthianandeswaren A, Christie M, et al. PIK3CA and PTEN gene and exon mutation-specific clinicopathologic and molecular associations in colorectal cancer. Clin Cancer Res 2013;19:3285-96.
5. Carpten JD, Faber AL, Horn C, Donoho GP, Briggs SL, Robbins CM, et al. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 2007;448:439-44.
6. Fan CD, Lum MA, Xu C, Black JD, Wang X. Ubiquitin-dependent regulation of phospho-AKT dynamics by the ubiquitin E3 ligase, NEDD4-1, in the insulin-like growth factor-1 response. J Biol Chem 2013;288:1674-84.
7. Kumar A, Purohit R. Cancer associated E17K mutation causes rapid conformational drift in AKT1 pleckstrin homology (PH) domain. PLoS One 2013;8:e64364.
8. Landgraf KE, Pilling C, Falke JJ. Molecular mechanism of an oncogenic mutation that alters membrane targeting: Glu17Lys modifies the PIP lipid specificity of the AKT1 PH domain. Biochemistry 2008;47:12260-9.
9. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platformfor exploring multidimensional cancer genomics data. Cancer Discov 2012;2:401-4.
10. Bosman F, Carneiro F: World Health Organization classification of tumours, pathology and genetics of tumours of the digestive system. Lyon, France: IARC Press; 2010.
11. Arcila M, Lau C, Nafa K, Ladanyi M. Detection of KRAS and BRAFmutations in colorectal carcinoma roles for high-sensitivity locked nucleic acid-PCR sequencing and broad-spectrum mass spectrometry genotyping. J Mol Diagn 2011;13:64-73.
12. Shia J, Klimstra DS, Nafa K, Offit K, Guillem JG, Markowitz AJ, et al. Value of immunohistochemical detection of DNA mismatch repair proteins in predicting germline mutation in hereditary colorectal neoplasms. Am J Surg Pathol 2005;29:96-104.
13. Gorovets D, Kannan K, Shen R, Kastenhuber ER, Islamdoust N, Campos C, et al. IDHmutation and neuroglial developmental features define clinically distinct subclasses of lower grade diffuse astrocytic glioma. Clin Cancer Res 2012;18:2490-501.
14. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, et al. Intratumor heterogeneity and branched evolution revealed bymultiregion sequencing. N Engl J Med 2012;366:883-92.
15. Rebucci M, Peixoto P, Dewitte A, Wattez N, DeNuncques MA, Rezvoy N, et al. Mechanisms underlying resistance to cetuximab in the HNSCC cell line: role of AKT inhibition in bypassing this resistance. Int J Oncol 2011;38:189-200.
16. Samowitz WS, Sweeney C, Herrick J, Albertsen H, Levin TR, Murtaugh MA, et al. Poor survival associated with the BRAF V600E mutation in microsatellitestable colon cancers. Cancer Res 2005;65:6063-9.
17. Zhao L, Vogt PK. Helical domain and kinase domain mutations in p110alpha of phosphatidylinositol 3-kinase induce gain of function by different mechanisms. Proc Natl Acad Sci U S A 2008;105:2652-7.
18. Rudd ML, Price JC, Fogoros S, Godwin AK, Sgroi DC, Merino MJ, et al. A unique spectrum of somatic PIK3CA (p110alpha) mutations within primary endometrial carcinomas. Clin Cancer Res 2011;17:1331-40.